Frontiers in Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1016440, encodeId=01c710164407b, content=偏重的研究方向：肿瘤 经验分享：请问一下，投稿时的文献类型可以让编辑重新更改吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ba15493073, createdName=51lll, createdTime=Sat Sep 11 01:19:04 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052990, encodeId=af39105299033, content=请问review is ongoing 从下面换到上面，期间一直存在，目前回来了审稿人2。3的意见，是还有审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7fb65143232, createdName=Fyjcfjbvgj, createdTime=Sun Sep 19 11:25:41 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053172, encodeId=acf810531e2a9, content=偏重的研究方向：肿瘤;免疫微环境 经验分享：看了上面很多生信文章才投的，说是生信友好。投稿一周，一直在编辑评估状态，最后被拒，要求实验验证？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f885490162, createdName=GXwangye, createdTime=Mon Sep 20 07:41:17 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003156, encodeId=80f2100315671, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ;诊断 经验分享：7.13小修，22号修回，27接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edd100244, createdName=DLMedu, createdTime=Tue Jul 27 22:48:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013352, encodeId=bba7101335213, content=有谁近期关于医学的,写中国医院投稿过的，都一头棒据掉吗，还是也有审稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef9a5219936, createdName=14779ba9m13暂无昵称, createdTime=Wed Sep 01 02:15:38 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009177, encodeId=9fce10091e764, content=偏重的研究方向：肿瘤 经验分享：请问大家，两个review is ongoing是指有两个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Wed Aug 18 16:40:48 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008664, encodeId=c7af100866497, content=偏重的研究方向：肿瘤 经验分享：这个杂志算是比较友好得了 6分多的杂志但是手上有两三分水平的文章可以投试试很容易中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Tue Aug 17 12:00:12 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006826, encodeId=49f91006826df, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：历时最久一次投稿，期间审稿人2小修后突然退出审稿。 Date Updates 09 Aug 2021 Article accepted for publication. 07 Aug 2021 Review of Review Editor 3 finalized. 05 Aug 2021 You posted new comments. 30 Jul 2021 Review of Review Editor 1 finalized. 19 Jul 2021 You posted new comments. You posted new comments. Review Editor 2 posted new comments. Review Editor 2 posted new comments. 08 Jul 2021 Corresponding Author re-submitted manuscript. 29 Jun 2021 Interactive review forum activated. 14 Mar 2021 Corresponding Author , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Aug 11 03:31:32 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003113, encodeId=8860100311362, content=偏重的研究方向：乳腺癌 经验分享：请问大家，是如何使用回复系统的，怎样算是回复审稿人了，不太会使用系统，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=46215471882, createdName=ms9000000943027010, createdTime=Tue Jul 27 20:17:26 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914308, encodeId=7d2291430892, content=返回去多久会有消息啊？快一个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8952252832, createdName=FPW, createdTime=Thu Jan 07 09:33:35 CST 2021, time=2021-01-07, status=1, ipAttribution=)]

2021-09-11 51lll

偏重的研究方向：肿瘤
经验分享：请问一下，投稿时的文献类型可以让编辑重新更改吗？

26 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1016440, encodeId=01c710164407b, content=偏重的研究方向：肿瘤 经验分享：请问一下，投稿时的文献类型可以让编辑重新更改吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ba15493073, createdName=51lll, createdTime=Sat Sep 11 01:19:04 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052990, encodeId=af39105299033, content=请问review is ongoing 从下面换到上面，期间一直存在，目前回来了审稿人2。3的意见，是还有审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7fb65143232, createdName=Fyjcfjbvgj, createdTime=Sun Sep 19 11:25:41 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053172, encodeId=acf810531e2a9, content=偏重的研究方向：肿瘤;免疫微环境 经验分享：看了上面很多生信文章才投的，说是生信友好。投稿一周，一直在编辑评估状态，最后被拒，要求实验验证？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f885490162, createdName=GXwangye, createdTime=Mon Sep 20 07:41:17 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003156, encodeId=80f2100315671, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ;诊断 经验分享：7.13小修，22号修回，27接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edd100244, createdName=DLMedu, createdTime=Tue Jul 27 22:48:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013352, encodeId=bba7101335213, content=有谁近期关于医学的,写中国医院投稿过的，都一头棒据掉吗，还是也有审稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef9a5219936, createdName=14779ba9m13暂无昵称, createdTime=Wed Sep 01 02:15:38 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009177, encodeId=9fce10091e764, content=偏重的研究方向：肿瘤 经验分享：请问大家，两个review is ongoing是指有两个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Wed Aug 18 16:40:48 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008664, encodeId=c7af100866497, content=偏重的研究方向：肿瘤 经验分享：这个杂志算是比较友好得了 6分多的杂志但是手上有两三分水平的文章可以投试试很容易中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Tue Aug 17 12:00:12 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006826, encodeId=49f91006826df, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：历时最久一次投稿，期间审稿人2小修后突然退出审稿。 Date Updates 09 Aug 2021 Article accepted for publication. 07 Aug 2021 Review of Review Editor 3 finalized. 05 Aug 2021 You posted new comments. 30 Jul 2021 Review of Review Editor 1 finalized. 19 Jul 2021 You posted new comments. You posted new comments. Review Editor 2 posted new comments. Review Editor 2 posted new comments. 08 Jul 2021 Corresponding Author re-submitted manuscript. 29 Jun 2021 Interactive review forum activated. 14 Mar 2021 Corresponding Author , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Aug 11 03:31:32 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003113, encodeId=8860100311362, content=偏重的研究方向：乳腺癌 经验分享：请问大家，是如何使用回复系统的，怎样算是回复审稿人了，不太会使用系统，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=46215471882, createdName=ms9000000943027010, createdTime=Tue Jul 27 20:17:26 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914308, encodeId=7d2291430892, content=返回去多久会有消息啊？快一个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8952252832, createdName=FPW, createdTime=Thu Jan 07 09:33:35 CST 2021, time=2021-01-07, status=1, ipAttribution=)]

2021-09-19 Fyjcfjbvgj

请问review is ongoing 从下面换到上面，期间一直存在，目前回来了审稿人2。3的意见，是还有审稿人？

32 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1016440, encodeId=01c710164407b, content=偏重的研究方向：肿瘤 经验分享：请问一下，投稿时的文献类型可以让编辑重新更改吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ba15493073, createdName=51lll, createdTime=Sat Sep 11 01:19:04 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052990, encodeId=af39105299033, content=请问review is ongoing 从下面换到上面，期间一直存在，目前回来了审稿人2。3的意见，是还有审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7fb65143232, createdName=Fyjcfjbvgj, createdTime=Sun Sep 19 11:25:41 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053172, encodeId=acf810531e2a9, content=偏重的研究方向：肿瘤;免疫微环境 经验分享：看了上面很多生信文章才投的，说是生信友好。投稿一周，一直在编辑评估状态，最后被拒，要求实验验证？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f885490162, createdName=GXwangye, createdTime=Mon Sep 20 07:41:17 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003156, encodeId=80f2100315671, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ;诊断 经验分享：7.13小修，22号修回，27接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edd100244, createdName=DLMedu, createdTime=Tue Jul 27 22:48:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013352, encodeId=bba7101335213, content=有谁近期关于医学的,写中国医院投稿过的，都一头棒据掉吗，还是也有审稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef9a5219936, createdName=14779ba9m13暂无昵称, createdTime=Wed Sep 01 02:15:38 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009177, encodeId=9fce10091e764, content=偏重的研究方向：肿瘤 经验分享：请问大家，两个review is ongoing是指有两个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Wed Aug 18 16:40:48 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008664, encodeId=c7af100866497, content=偏重的研究方向：肿瘤 经验分享：这个杂志算是比较友好得了 6分多的杂志但是手上有两三分水平的文章可以投试试很容易中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Tue Aug 17 12:00:12 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006826, encodeId=49f91006826df, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：历时最久一次投稿，期间审稿人2小修后突然退出审稿。 Date Updates 09 Aug 2021 Article accepted for publication. 07 Aug 2021 Review of Review Editor 3 finalized. 05 Aug 2021 You posted new comments. 30 Jul 2021 Review of Review Editor 1 finalized. 19 Jul 2021 You posted new comments. You posted new comments. Review Editor 2 posted new comments. Review Editor 2 posted new comments. 08 Jul 2021 Corresponding Author re-submitted manuscript. 29 Jun 2021 Interactive review forum activated. 14 Mar 2021 Corresponding Author , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Aug 11 03:31:32 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003113, encodeId=8860100311362, content=偏重的研究方向：乳腺癌 经验分享：请问大家，是如何使用回复系统的，怎样算是回复审稿人了，不太会使用系统，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=46215471882, createdName=ms9000000943027010, createdTime=Tue Jul 27 20:17:26 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914308, encodeId=7d2291430892, content=返回去多久会有消息啊？快一个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8952252832, createdName=FPW, createdTime=Thu Jan 07 09:33:35 CST 2021, time=2021-01-07, status=1, ipAttribution=)]

2021-09-20 GXwangye

偏重的研究方向：肿瘤;免疫微环境
经验分享：看了上面很多生信文章才投的，说是生信友好。投稿一周，一直在编辑评估状态，最后被拒，要求实验验证？

24 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1016440, encodeId=01c710164407b, content=偏重的研究方向：肿瘤 经验分享：请问一下，投稿时的文献类型可以让编辑重新更改吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ba15493073, createdName=51lll, createdTime=Sat Sep 11 01:19:04 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052990, encodeId=af39105299033, content=请问review is ongoing 从下面换到上面，期间一直存在，目前回来了审稿人2。3的意见，是还有审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7fb65143232, createdName=Fyjcfjbvgj, createdTime=Sun Sep 19 11:25:41 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053172, encodeId=acf810531e2a9, content=偏重的研究方向：肿瘤;免疫微环境 经验分享：看了上面很多生信文章才投的，说是生信友好。投稿一周，一直在编辑评估状态，最后被拒，要求实验验证？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f885490162, createdName=GXwangye, createdTime=Mon Sep 20 07:41:17 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003156, encodeId=80f2100315671, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ;诊断 经验分享：7.13小修，22号修回，27接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edd100244, createdName=DLMedu, createdTime=Tue Jul 27 22:48:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013352, encodeId=bba7101335213, content=有谁近期关于医学的,写中国医院投稿过的，都一头棒据掉吗，还是也有审稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef9a5219936, createdName=14779ba9m13暂无昵称, createdTime=Wed Sep 01 02:15:38 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009177, encodeId=9fce10091e764, content=偏重的研究方向：肿瘤 经验分享：请问大家，两个review is ongoing是指有两个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Wed Aug 18 16:40:48 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008664, encodeId=c7af100866497, content=偏重的研究方向：肿瘤 经验分享：这个杂志算是比较友好得了 6分多的杂志但是手上有两三分水平的文章可以投试试很容易中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Tue Aug 17 12:00:12 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006826, encodeId=49f91006826df, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：历时最久一次投稿，期间审稿人2小修后突然退出审稿。 Date Updates 09 Aug 2021 Article accepted for publication. 07 Aug 2021 Review of Review Editor 3 finalized. 05 Aug 2021 You posted new comments. 30 Jul 2021 Review of Review Editor 1 finalized. 19 Jul 2021 You posted new comments. You posted new comments. Review Editor 2 posted new comments. Review Editor 2 posted new comments. 08 Jul 2021 Corresponding Author re-submitted manuscript. 29 Jun 2021 Interactive review forum activated. 14 Mar 2021 Corresponding Author , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Aug 11 03:31:32 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003113, encodeId=8860100311362, content=偏重的研究方向：乳腺癌 经验分享：请问大家，是如何使用回复系统的，怎样算是回复审稿人了，不太会使用系统，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=46215471882, createdName=ms9000000943027010, createdTime=Tue Jul 27 20:17:26 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914308, encodeId=7d2291430892, content=返回去多久会有消息啊？快一个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8952252832, createdName=FPW, createdTime=Thu Jan 07 09:33:35 CST 2021, time=2021-01-07, status=1, ipAttribution=)]

2021-07-27 DLMedu

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤 ;诊断
经验分享：7.13小修，22号修回，27接收。

26 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1016440, encodeId=01c710164407b, content=偏重的研究方向：肿瘤 经验分享：请问一下，投稿时的文献类型可以让编辑重新更改吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ba15493073, createdName=51lll, createdTime=Sat Sep 11 01:19:04 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052990, encodeId=af39105299033, content=请问review is ongoing 从下面换到上面，期间一直存在，目前回来了审稿人2。3的意见，是还有审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7fb65143232, createdName=Fyjcfjbvgj, createdTime=Sun Sep 19 11:25:41 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053172, encodeId=acf810531e2a9, content=偏重的研究方向：肿瘤;免疫微环境 经验分享：看了上面很多生信文章才投的，说是生信友好。投稿一周，一直在编辑评估状态，最后被拒，要求实验验证？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f885490162, createdName=GXwangye, createdTime=Mon Sep 20 07:41:17 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003156, encodeId=80f2100315671, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ;诊断 经验分享：7.13小修，22号修回，27接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edd100244, createdName=DLMedu, createdTime=Tue Jul 27 22:48:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013352, encodeId=bba7101335213, content=有谁近期关于医学的,写中国医院投稿过的，都一头棒据掉吗，还是也有审稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef9a5219936, createdName=14779ba9m13暂无昵称, createdTime=Wed Sep 01 02:15:38 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009177, encodeId=9fce10091e764, content=偏重的研究方向：肿瘤 经验分享：请问大家，两个review is ongoing是指有两个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Wed Aug 18 16:40:48 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008664, encodeId=c7af100866497, content=偏重的研究方向：肿瘤 经验分享：这个杂志算是比较友好得了 6分多的杂志但是手上有两三分水平的文章可以投试试很容易中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Tue Aug 17 12:00:12 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006826, encodeId=49f91006826df, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：历时最久一次投稿，期间审稿人2小修后突然退出审稿。 Date Updates 09 Aug 2021 Article accepted for publication. 07 Aug 2021 Review of Review Editor 3 finalized. 05 Aug 2021 You posted new comments. 30 Jul 2021 Review of Review Editor 1 finalized. 19 Jul 2021 You posted new comments. You posted new comments. Review Editor 2 posted new comments. Review Editor 2 posted new comments. 08 Jul 2021 Corresponding Author re-submitted manuscript. 29 Jun 2021 Interactive review forum activated. 14 Mar 2021 Corresponding Author , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Aug 11 03:31:32 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003113, encodeId=8860100311362, content=偏重的研究方向：乳腺癌 经验分享：请问大家，是如何使用回复系统的，怎样算是回复审稿人了，不太会使用系统，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=46215471882, createdName=ms9000000943027010, createdTime=Tue Jul 27 20:17:26 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914308, encodeId=7d2291430892, content=返回去多久会有消息啊？快一个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8952252832, createdName=FPW, createdTime=Thu Jan 07 09:33:35 CST 2021, time=2021-01-07, status=1, ipAttribution=)]

2021-09-01 14779ba9m13暂无昵称

有谁近期关于医学的,写中国医院投稿过的，都一头棒据掉吗，还是也有审稿的？

39 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1016440, encodeId=01c710164407b, content=偏重的研究方向：肿瘤 经验分享：请问一下，投稿时的文献类型可以让编辑重新更改吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ba15493073, createdName=51lll, createdTime=Sat Sep 11 01:19:04 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052990, encodeId=af39105299033, content=请问review is ongoing 从下面换到上面，期间一直存在，目前回来了审稿人2。3的意见，是还有审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7fb65143232, createdName=Fyjcfjbvgj, createdTime=Sun Sep 19 11:25:41 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053172, encodeId=acf810531e2a9, content=偏重的研究方向：肿瘤;免疫微环境 经验分享：看了上面很多生信文章才投的，说是生信友好。投稿一周，一直在编辑评估状态，最后被拒，要求实验验证？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f885490162, createdName=GXwangye, createdTime=Mon Sep 20 07:41:17 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003156, encodeId=80f2100315671, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ;诊断 经验分享：7.13小修，22号修回，27接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edd100244, createdName=DLMedu, createdTime=Tue Jul 27 22:48:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013352, encodeId=bba7101335213, content=有谁近期关于医学的,写中国医院投稿过的，都一头棒据掉吗，还是也有审稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef9a5219936, createdName=14779ba9m13暂无昵称, createdTime=Wed Sep 01 02:15:38 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009177, encodeId=9fce10091e764, content=偏重的研究方向：肿瘤 经验分享：请问大家，两个review is ongoing是指有两个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Wed Aug 18 16:40:48 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008664, encodeId=c7af100866497, content=偏重的研究方向：肿瘤 经验分享：这个杂志算是比较友好得了 6分多的杂志但是手上有两三分水平的文章可以投试试很容易中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Tue Aug 17 12:00:12 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006826, encodeId=49f91006826df, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：历时最久一次投稿，期间审稿人2小修后突然退出审稿。 Date Updates 09 Aug 2021 Article accepted for publication. 07 Aug 2021 Review of Review Editor 3 finalized. 05 Aug 2021 You posted new comments. 30 Jul 2021 Review of Review Editor 1 finalized. 19 Jul 2021 You posted new comments. You posted new comments. Review Editor 2 posted new comments. Review Editor 2 posted new comments. 08 Jul 2021 Corresponding Author re-submitted manuscript. 29 Jun 2021 Interactive review forum activated. 14 Mar 2021 Corresponding Author , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Aug 11 03:31:32 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003113, encodeId=8860100311362, content=偏重的研究方向：乳腺癌 经验分享：请问大家，是如何使用回复系统的，怎样算是回复审稿人了，不太会使用系统，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=46215471882, createdName=ms9000000943027010, createdTime=Tue Jul 27 20:17:26 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914308, encodeId=7d2291430892, content=返回去多久会有消息啊？快一个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8952252832, createdName=FPW, createdTime=Thu Jan 07 09:33:35 CST 2021, time=2021-01-07, status=1, ipAttribution=)]

2021-08-18 122220a4m01暂无昵称

偏重的研究方向：肿瘤
经验分享：请问大家，两个review is ongoing是指有两个审稿人？

39 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1016440, encodeId=01c710164407b, content=偏重的研究方向：肿瘤 经验分享：请问一下，投稿时的文献类型可以让编辑重新更改吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ba15493073, createdName=51lll, createdTime=Sat Sep 11 01:19:04 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052990, encodeId=af39105299033, content=请问review is ongoing 从下面换到上面，期间一直存在，目前回来了审稿人2。3的意见，是还有审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7fb65143232, createdName=Fyjcfjbvgj, createdTime=Sun Sep 19 11:25:41 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053172, encodeId=acf810531e2a9, content=偏重的研究方向：肿瘤;免疫微环境 经验分享：看了上面很多生信文章才投的，说是生信友好。投稿一周，一直在编辑评估状态，最后被拒，要求实验验证？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f885490162, createdName=GXwangye, createdTime=Mon Sep 20 07:41:17 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003156, encodeId=80f2100315671, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ;诊断 经验分享：7.13小修，22号修回，27接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edd100244, createdName=DLMedu, createdTime=Tue Jul 27 22:48:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013352, encodeId=bba7101335213, content=有谁近期关于医学的,写中国医院投稿过的，都一头棒据掉吗，还是也有审稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef9a5219936, createdName=14779ba9m13暂无昵称, createdTime=Wed Sep 01 02:15:38 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009177, encodeId=9fce10091e764, content=偏重的研究方向：肿瘤 经验分享：请问大家，两个review is ongoing是指有两个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Wed Aug 18 16:40:48 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008664, encodeId=c7af100866497, content=偏重的研究方向：肿瘤 经验分享：这个杂志算是比较友好得了 6分多的杂志但是手上有两三分水平的文章可以投试试很容易中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Tue Aug 17 12:00:12 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006826, encodeId=49f91006826df, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：历时最久一次投稿，期间审稿人2小修后突然退出审稿。 Date Updates 09 Aug 2021 Article accepted for publication. 07 Aug 2021 Review of Review Editor 3 finalized. 05 Aug 2021 You posted new comments. 30 Jul 2021 Review of Review Editor 1 finalized. 19 Jul 2021 You posted new comments. You posted new comments. Review Editor 2 posted new comments. Review Editor 2 posted new comments. 08 Jul 2021 Corresponding Author re-submitted manuscript. 29 Jun 2021 Interactive review forum activated. 14 Mar 2021 Corresponding Author , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Aug 11 03:31:32 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003113, encodeId=8860100311362, content=偏重的研究方向：乳腺癌 经验分享：请问大家，是如何使用回复系统的，怎样算是回复审稿人了，不太会使用系统，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=46215471882, createdName=ms9000000943027010, createdTime=Tue Jul 27 20:17:26 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914308, encodeId=7d2291430892, content=返回去多久会有消息啊？快一个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8952252832, createdName=FPW, createdTime=Thu Jan 07 09:33:35 CST 2021, time=2021-01-07, status=1, ipAttribution=)]

2021-08-17 ms9000000537367142

偏重的研究方向：肿瘤
经验分享：这个杂志算是比较友好得了 6分多的杂志但是手上有两三分水平的文章可以投试试很容易中

37 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1016440, encodeId=01c710164407b, content=偏重的研究方向：肿瘤 经验分享：请问一下，投稿时的文献类型可以让编辑重新更改吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ba15493073, createdName=51lll, createdTime=Sat Sep 11 01:19:04 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052990, encodeId=af39105299033, content=请问review is ongoing 从下面换到上面，期间一直存在，目前回来了审稿人2。3的意见，是还有审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7fb65143232, createdName=Fyjcfjbvgj, createdTime=Sun Sep 19 11:25:41 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053172, encodeId=acf810531e2a9, content=偏重的研究方向：肿瘤;免疫微环境 经验分享：看了上面很多生信文章才投的，说是生信友好。投稿一周，一直在编辑评估状态，最后被拒，要求实验验证？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f885490162, createdName=GXwangye, createdTime=Mon Sep 20 07:41:17 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003156, encodeId=80f2100315671, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ;诊断 经验分享：7.13小修，22号修回，27接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edd100244, createdName=DLMedu, createdTime=Tue Jul 27 22:48:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013352, encodeId=bba7101335213, content=有谁近期关于医学的,写中国医院投稿过的，都一头棒据掉吗，还是也有审稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef9a5219936, createdName=14779ba9m13暂无昵称, createdTime=Wed Sep 01 02:15:38 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009177, encodeId=9fce10091e764, content=偏重的研究方向：肿瘤 经验分享：请问大家，两个review is ongoing是指有两个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Wed Aug 18 16:40:48 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008664, encodeId=c7af100866497, content=偏重的研究方向：肿瘤 经验分享：这个杂志算是比较友好得了 6分多的杂志但是手上有两三分水平的文章可以投试试很容易中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Tue Aug 17 12:00:12 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006826, encodeId=49f91006826df, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：历时最久一次投稿，期间审稿人2小修后突然退出审稿。 Date Updates 09 Aug 2021 Article accepted for publication. 07 Aug 2021 Review of Review Editor 3 finalized. 05 Aug 2021 You posted new comments. 30 Jul 2021 Review of Review Editor 1 finalized. 19 Jul 2021 You posted new comments. You posted new comments. Review Editor 2 posted new comments. Review Editor 2 posted new comments. 08 Jul 2021 Corresponding Author re-submitted manuscript. 29 Jun 2021 Interactive review forum activated. 14 Mar 2021 Corresponding Author , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Aug 11 03:31:32 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003113, encodeId=8860100311362, content=偏重的研究方向：乳腺癌 经验分享：请问大家，是如何使用回复系统的，怎样算是回复审稿人了，不太会使用系统，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=46215471882, createdName=ms9000000943027010, createdTime=Tue Jul 27 20:17:26 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914308, encodeId=7d2291430892, content=返回去多久会有消息啊？快一个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8952252832, createdName=FPW, createdTime=Thu Jan 07 09:33:35 CST 2021, time=2021-01-07, status=1, ipAttribution=)]

2021-08-11 1dd96cb3m86(暂无匿称)

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：历时最久一次投稿，期间审稿人2小修后突然退出审稿。 Date Updates 09 Aug 2021 Article accepted for publication. 07 Aug 2021 Review of Review Editor 3 finalized. 05 Aug 2021 You posted new comments. 30 Jul 2021 Review of Review Editor 1 finalized. 19 Jul 2021 You posted new comments. You posted new comments. Review Editor 2 posted new comments. Review Editor 2 posted new comments. 08 Jul 2021 Corresponding Author re-submitted manuscript. 29 Jun 2021 Interactive review forum activated. 14 Mar 2021 Corresponding Author

39 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1016440, encodeId=01c710164407b, content=偏重的研究方向：肿瘤 经验分享：请问一下，投稿时的文献类型可以让编辑重新更改吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ba15493073, createdName=51lll, createdTime=Sat Sep 11 01:19:04 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052990, encodeId=af39105299033, content=请问review is ongoing 从下面换到上面，期间一直存在，目前回来了审稿人2。3的意见，是还有审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7fb65143232, createdName=Fyjcfjbvgj, createdTime=Sun Sep 19 11:25:41 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053172, encodeId=acf810531e2a9, content=偏重的研究方向：肿瘤;免疫微环境 经验分享：看了上面很多生信文章才投的，说是生信友好。投稿一周，一直在编辑评估状态，最后被拒，要求实验验证？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f885490162, createdName=GXwangye, createdTime=Mon Sep 20 07:41:17 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003156, encodeId=80f2100315671, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ;诊断 经验分享：7.13小修，22号修回，27接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edd100244, createdName=DLMedu, createdTime=Tue Jul 27 22:48:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013352, encodeId=bba7101335213, content=有谁近期关于医学的,写中国医院投稿过的，都一头棒据掉吗，还是也有审稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef9a5219936, createdName=14779ba9m13暂无昵称, createdTime=Wed Sep 01 02:15:38 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009177, encodeId=9fce10091e764, content=偏重的研究方向：肿瘤 经验分享：请问大家，两个review is ongoing是指有两个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Wed Aug 18 16:40:48 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008664, encodeId=c7af100866497, content=偏重的研究方向：肿瘤 经验分享：这个杂志算是比较友好得了 6分多的杂志但是手上有两三分水平的文章可以投试试很容易中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Tue Aug 17 12:00:12 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006826, encodeId=49f91006826df, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：历时最久一次投稿，期间审稿人2小修后突然退出审稿。 Date Updates 09 Aug 2021 Article accepted for publication. 07 Aug 2021 Review of Review Editor 3 finalized. 05 Aug 2021 You posted new comments. 30 Jul 2021 Review of Review Editor 1 finalized. 19 Jul 2021 You posted new comments. You posted new comments. Review Editor 2 posted new comments. Review Editor 2 posted new comments. 08 Jul 2021 Corresponding Author re-submitted manuscript. 29 Jun 2021 Interactive review forum activated. 14 Mar 2021 Corresponding Author , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Aug 11 03:31:32 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003113, encodeId=8860100311362, content=偏重的研究方向：乳腺癌 经验分享：请问大家，是如何使用回复系统的，怎样算是回复审稿人了，不太会使用系统，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=46215471882, createdName=ms9000000943027010, createdTime=Tue Jul 27 20:17:26 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914308, encodeId=7d2291430892, content=返回去多久会有消息啊？快一个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8952252832, createdName=FPW, createdTime=Thu Jan 07 09:33:35 CST 2021, time=2021-01-07, status=1, ipAttribution=)]

2021-07-27 ms9000000943027010

偏重的研究方向：乳腺癌
经验分享：请问大家，是如何使用回复系统的，怎样算是回复审稿人了，不太会使用系统，有点着急

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1016440, encodeId=01c710164407b, content=偏重的研究方向：肿瘤 经验分享：请问一下，投稿时的文献类型可以让编辑重新更改吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ba15493073, createdName=51lll, createdTime=Sat Sep 11 01:19:04 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052990, encodeId=af39105299033, content=请问review is ongoing 从下面换到上面，期间一直存在，目前回来了审稿人2。3的意见，是还有审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7fb65143232, createdName=Fyjcfjbvgj, createdTime=Sun Sep 19 11:25:41 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053172, encodeId=acf810531e2a9, content=偏重的研究方向：肿瘤;免疫微环境 经验分享：看了上面很多生信文章才投的，说是生信友好。投稿一周，一直在编辑评估状态，最后被拒，要求实验验证？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8f885490162, createdName=GXwangye, createdTime=Mon Sep 20 07:41:17 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003156, encodeId=80f2100315671, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ;诊断 经验分享：7.13小修，22号修回，27接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edd100244, createdName=DLMedu, createdTime=Tue Jul 27 22:48:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013352, encodeId=bba7101335213, content=有谁近期关于医学的,写中国医院投稿过的，都一头棒据掉吗，还是也有审稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef9a5219936, createdName=14779ba9m13暂无昵称, createdTime=Wed Sep 01 02:15:38 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009177, encodeId=9fce10091e764, content=偏重的研究方向：肿瘤 经验分享：请问大家，两个review is ongoing是指有两个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f72309028, createdName=122220a4m01暂无昵称, createdTime=Wed Aug 18 16:40:48 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008664, encodeId=c7af100866497, content=偏重的研究方向：肿瘤 经验分享：这个杂志算是比较友好得了 6分多的杂志但是手上有两三分水平的文章可以投试试很容易中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Tue Aug 17 12:00:12 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006826, encodeId=49f91006826df, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：历时最久一次投稿，期间审稿人2小修后突然退出审稿。 Date Updates 09 Aug 2021 Article accepted for publication. 07 Aug 2021 Review of Review Editor 3 finalized. 05 Aug 2021 You posted new comments. 30 Jul 2021 Review of Review Editor 1 finalized. 19 Jul 2021 You posted new comments. You posted new comments. Review Editor 2 posted new comments. Review Editor 2 posted new comments. 08 Jul 2021 Corresponding Author re-submitted manuscript. 29 Jun 2021 Interactive review forum activated. 14 Mar 2021 Corresponding Author , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Aug 11 03:31:32 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003113, encodeId=8860100311362, content=偏重的研究方向：乳腺癌 经验分享：请问大家，是如何使用回复系统的，怎样算是回复审稿人了，不太会使用系统，有点着急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=46215471882, createdName=ms9000000943027010, createdTime=Tue Jul 27 20:17:26 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914308, encodeId=7d2291430892, content=返回去多久会有消息啊？快一个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8952252832, createdName=FPW, createdTime=Thu Jan 07 09:33:35 CST 2021, time=2021-01-07, status=1, ipAttribution=)]

2021-01-07 FPW

返回去多久会有消息啊？快一个月了

76 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务